Last checked at 2 Sep 2021 07:00
2 September 2021
GENinCode Plc
("GENinCode" or the "Company")
Notice of results
Analyst briefing and investor presentation
GENinCode Plc (AIM: GENI), the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces that its interim results for the six months ended 30 June 2021 will be released on Thursday, 16 September 2021.
Analyst briefing
A briefing open to analysts will take place remotely via video conference call on Thursday, 16 September at 11.30 a.m. (BST). If you would like to register for this call, please contact Walbrook PR at GENinCode@walbrookpr.com.
Investor presentation
Chief Executive Officer, Matthew Walls, and Chief Financial Officer, Paul Foulger, will also provide a live presentation relating to GENinCode plc's interim results via the Investor Meet Company platform on 16 September 2021 at 16:00 p.m. (BST).
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 a.m. (BST) the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet GENinCode plc via:
https://www.investormeetcompany.com/genincode-plc/register-investor
Investors who already follow GENinCode plc on the Investor Meet Company platform will automatically be invited.
Contacts:
GENinCode plc | www.genincode.com | |||
Matthew Walls, CEO | Via Walbrook PR | |||
Paul Foulger, CFO | ||||
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | |||
Alex Price / Ben Maddison / Richard Short | ||||
Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | |||
Giles Balleny | ||||
Dale Bellis / Michael Johnson (Sales) | ||||
Walbrook PR Limited | Tel: 020 7933 8780 or genincode@walbrookpr.com | |||
Anna Dunphy / Paul McManus / Louis Ashe-Jepson | ||||
About GENinCode plc
GENinCode plc (AIM: GENI) is engaged in the risk assessment, prediction and prevention of cardiovascular disease ("CVD"). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company's products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD.
The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. The Directors believe that approximately €50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.